ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
ERBB2 (HER2/neu)
cancer immunotherapy
chimeric antigen receptor
rhabdomyosarcoma
xenograft
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
05
2023
accepted:
27
07
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR) technology to natural killer (NK) cells may offer safe, effective, and affordable therapies that enhance cancer immune surveillance. Here, we assess the efficacy of clinically usable CAR-engineered NK cell line NK-92/5.28.z against ErbB2-positive RMS Our results show that NK-92/5.28.z cells effectively kill RMS cells These findings encourage further development of NK-92/5.28.z cells as off-the-shelf immunotherapy for the treatment of metastatic RMS.
Identifiants
pubmed: 37662907
doi: 10.3389/fimmu.2023.1228894
pmc: PMC10471977
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228894Informations de copyright
Copyright © 2023 Heim, Moser, Kreyenberg, Bonig, Tonn, Wels, Gradhand, Ullrich, Meister, Koerkamp, Holstege, Drost, Klusmann, Bader, Merker and Rettinger.
Déclaration de conflit d'intérêts
J-HK has advisory roles for Bluebird Bio, Novartis, Roche and Jazz Pharmaceuticals. TT and WW are named as inventors on patents and patent applications related to the study therapeutic owned by their respective academic institutions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33468562
Children (Basel). 2018 Dec 10;5(12):
pubmed: 30544742
J Transl Med. 2022 Apr 2;20(1):151
pubmed: 35366943
Front Immunol. 2019 Nov 14;10:2683
pubmed: 31798595
Nat Commun. 2023 May 27;14(1):3074
pubmed: 37244912
Leukemia. 1994 Apr;8(4):652-8
pubmed: 8152260
Mol Ther. 2015 Feb;23(2):330-8
pubmed: 25373520
Nat Rev Dis Primers. 2019 Jan 7;5(1):1
pubmed: 30617281
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
Front Oncol. 2013 Jul 17;3:183
pubmed: 23882450
Oncotarget. 2017 Jul 12;8(51):89256-89268
pubmed: 29179517
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Biotechnology (N Y). 1992 Oct;10(10):1128-32
pubmed: 1369487
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Expert Opin Biol Ther. 2020 May;20(5):503-516
pubmed: 32125191
Cancer Immunol Immunother. 2018 Jan;67(1):25-38
pubmed: 28879551
Sci Rep. 2019 Jun 25;9(1):9211
pubmed: 31239476
Semin Pediatr Surg. 2016 Oct;25(5):276-283
pubmed: 27955730
Mod Pathol. 2006 Sep;19(9):1213-20
pubmed: 16729016
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Pediatr Blood Cancer. 2017 Sep;64(9):
pubmed: 28233470
Adolesc Health Med Ther. 2014 Jun 17;5:115-25
pubmed: 24966711
Front Immunol. 2023 Mar 20;14:1113882
pubmed: 37020537
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
Pediatr Blood Cancer. 2013 Jun;60(6):1001-8
pubmed: 23255356
Cancer. 2009 Sep 15;115(18):4218-26
pubmed: 19536876
Cancer Cell Int. 2021 Jan 20;21(1):62
pubmed: 33472628
EMBO Mol Med. 2022 Oct 10;14(10):e16001
pubmed: 35916583
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4318-22
pubmed: 7910405
Cancer. 2007 Nov 15;110(10):2293-303
pubmed: 17896786
Front Immunol. 2017 May 18;8:533
pubmed: 28572802
Pediatr Blood Cancer. 2020 May;67(5):e28219
pubmed: 32100935
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Blood. 2013 Sep 19;122(12):2030-8
pubmed: 23884859
Int J Cancer. 2000 Jul 1;87(1):29-36
pubmed: 10861449
Nat Commun. 2020 Jul 15;11(1):3549
pubmed: 32669548
J Vis Exp. 2016 Jul 07;(113):
pubmed: 27501019
Cells. 2020 Apr 16;9(4):
pubmed: 32316260
Transfus Med Hemother. 2016 Mar;43(2):89-95
pubmed: 27226791
Front Immunol. 2020 Oct 19;11:581468
pubmed: 33193388
J Natl Cancer Inst. 2015 Dec 06;108(5):
pubmed: 26640245
Front Immunol. 2021 Dec 01;12:732135
pubmed: 34925314
Cancers (Basel). 2021 Mar 22;13(6):
pubmed: 33809981
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33807011
Front Oncol. 2021 Jan 29;10:600980
pubmed: 33585217